financingEurope’s life sciences investors step up as biotech financing gap widensEurope produces world-class life sciences research, yet still struggles to finance and scale it. Venture capital in European biotech accounts for just 7 per cent of global funding, while 66 of the 67 … more ➔
AIZeon invests in Chemify to cut compound synthesis time using AI and roboticsChemify has struck a deal with Zeon, securing investment from the company’s venture capital wing and signing up to make novel compounds and materials for its new partner. more ➔
SANOFISanofiFrom Darmstadt to Paris: Belén Garijo leaves Merck to lead Sanofi after CEO exitA surprise move from Darmstadt to Paris: outgoing Merck CEO Belén Garijo is set to take the helm at French pharmaceutical group Sanofi after Paul Hudson unexpectedly failed to secure a contract extension … more ➔
rare diseasesFrench biopharma duo THX Pharma and Biocodex strike rare diseases licensing deal worth up to €173MFrench biopharma THX Pharma has signed a strategic licensing deal with Biocodex, an independent French pharmaceutical group, to advance two drug candidates in three rare genetic disorders with high unmet … more ➔
Microbioticaclinical dataMicrobiotica’s microbiome therapy showed 63% remission in ulcerative colitis phase 1b trialCambridge-based Microbiotica’s ulcerative colitis (UC) candidate met its primary and secondary phase 1b study objectives on safety, efficacy signals and bacterial engraftment. The company has reported … more ➔
Araris Biotech AGAntibody drug conjugatesSwiss-Japanese ADC player Araris expands Chugai pact with $780m licensing agreementZurich-based oncology biotech Araris Biotech AG has entered into a research collaboration with an option to license with Japan’s Chugai Pharmaceutical, a subsidiary of Roche. The aim of the partnership … more ➔
Freepik.comAntibodyThis Memo sticks: CSL bites in Switzerland for antibody collaborationThe Australian–Swiss plasma specialist CSL is relying on technology from Switzerland for recombinant polyclonal immunoglobulins (IgG). With Memo Therapeutics, the company has entered into a collaboration … more ➔
financing4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritisAfter more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy … more ➔
© Bayer LeverkusenStrokeBayer: At last, success with coagulation factor XIa in phase 3 stroke trialBayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class … more ➔
FundraisingDublin-based Aerska secures $39M Series A to push RNA medicines into the brainAerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was … more ➔
SANOFI
Microbiotica
Araris Biotech AG
Freepik.com
© Bayer Leverkusen
